• Valion Bio named Thomas H. Jensen as board chair to steer development of Entolimod for acute radiation syndrome.
• Jensen is CEO and a director of Nasdaq-listed Allarity Therapeutics with more than 20 years of biotech and oncology experience.
• At Allarity, he led a strategic refocus around lead asset stenoparib, streamlined operations, cut costs, advanced a Phase 2 ovarian cancer program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.